Savara Inc. (NASDAQ:SVRA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Savara Inc. (NASDAQ:SVRA) have been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $10.1429.

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Savara from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research report on Tuesday, April 21st. William Blair set a $10.00 price objective on shares of Savara in a research note on Monday, March 16th. Oppenheimer initiated coverage on Savara in a research report on Friday, April 24th. They set an “outperform” rating and a $11.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday, March 16th.

Savara Trading Down 2.6%

Shares of SVRA stock opened at $4.93 on Wednesday. Savara has a fifty-two week low of $1.98 and a fifty-two week high of $7.01. The stock has a market cap of $1.01 billion, a P/E ratio of -8.80 and a beta of 0.26. The business has a fifty day simple moving average of $5.30 and a 200-day simple moving average of $5.59. The company has a quick ratio of 13.47, a current ratio of 13.47 and a debt-to-equity ratio of 0.17.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). On average, analysts forecast that Savara will post -0.57 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Swedbank AB grew its holdings in shares of Savara by 54.5% during the fourth quarter. Swedbank AB now owns 850,000 shares of the company’s stock worth $5,126,000 after buying an additional 300,000 shares in the last quarter. F m Investments LLC lifted its stake in shares of Savara by 56.5% during the fourth quarter. F m Investments LLC now owns 678,813 shares of the company’s stock valued at $4,093,000 after buying an additional 245,100 shares during the period. Nan Fung Trinity HK Ltd. purchased a new position in shares of Savara during the fourth quarter valued at approximately $10,182,000. Rosalind Advisors Inc. boosted its position in Savara by 50.7% during the third quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock worth $14,280,000 after acquiring an additional 1,345,056 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Savara by 20.8% during the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company’s stock worth $60,551,000 after acquiring an additional 1,728,453 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.